Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of CK-0045 Following Subcutaneous Administration in Healthy Participants and Otherwise Healthy Participants With Obesity

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of CK-0045 Following Subcutaneous Administration in Healthy Participants and Otherwise Healthy Participants With Obesity

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CK 0045 (Primary) ; CK 0045 (Primary)
  • Indications Obesity
  • Focus Adverse reactions
  • Sponsors Cytoki Pharma

Most Recent Events

  • 25 Jul 2024 announced positive data from
  • 09 Jan 2024 Status changed from active, no longer recruiting to completed.
  • 27 Nov 2023 Experimental: Multiple ascending dose (MAD) treatment arm is updated to reduce the number of dose levels from 4 to 3. Thus, only dose level 1 to dose level 3 will be studied.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top